biostudies-literatureBlair TCNCI NIH HHSProvidence Foundations of OregonNIHe202101337https://www.ebi.ac.uk/biostudies/studies/S-EPMC9058260biostudies-literatureUnknown5(9)Radiation therapy generates extensive cancer cell death capable of promoting tumor-specific immunity. Within the tumor, conventional dendritic cells (cDCs) are known to carry tumor-associated antigens to the draining lymph node (TdLN) where they initiate T-cell priming. How radiation influences cDC migration is poorly understood. Here, we show that immunological efficacy of radiation therapy is dependent on cDC migration in radioimmunogenic tumors. Using photoconvertible mice, we demonstrate that radiation impairs cDC migration to the TdLN in poorly radioimmunogenic tumors. Comparative transcriptional analysis revealed that cDCs in radioimmunogenic tumors express genes associated with activation of endogenous adjuvant signaling pathways when compared with poorly radioimmunogenic tumors. MoLife science allianceFluorescent tracking identifies key migratory dendritic cells in the lymph node after radiotherapy.PMC9058260R01 CA182311R01CA182311R01 CA244142R01CA208644R21 CA277250R01 CA208644Piening BDGough MJBaird JRBambina SDowdell AKLund AWCrittenden MRKramer GFAlice AFBlair TCfalseFluorescent tracking identifies key migratory dendritic cells in the lymph node after radiotherapy.Radiation therapy generates extensive cancer cell death capable of promoting tumor-specific immunity. Within the tumor, conventional dendritic cells (cDCs) are known to carry tumor-associated antigens to the draining lymph node (TdLN) where they initiate T-cell priming. How radiation influences cDC migration is poorly understood. Here, we show that immunological efficacy of radiation therapy is dependent on cDC migration in radioimmunogenic tumors. Using photoconvertible mice, we demonstrate that radiation impairs cDC migration to the TdLN in poorly radioimmunogenic tumors. Comparative transcriptional analysis revealed that cDCs in radioimmunogenic tumors express genes associated with activation of endogenous adjuvant signaling pathways when compared with poorly radioimmunogenic tumors. Mo2022-01-01T00:00:00Z2022 Sep2026-05-09T23:39:54.921Z2025-04-04T19:33:32.839ZS-EPMC90582603548769510.26508/lsa.202101337